Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: CellCept, Myfortic
Mycophenolic acid is an immunosuppressant drug used primarily to prevent organ rejection after transplantation. It is a prodrug of mycophenolic acid, which inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo purine synthesis pathway. This selectively inhibits the proliferation of lymphocytes, crucial cells in the immune response, thereby reducing the risk of organ rejection.
Prevention of organ rejection after kidney, heart, and liver transplants.
Mycophenolic acid increases the risk of infections, including serious and potentially fatal infections. It also increases the risk of certain types of cancer, including skin cancer and lymphoma. Patients should be monitored closely for signs and symptoms of infection and cancer.
Outcome:
Increased risk of bone marrow suppression
Mechanism:
Additive myelosuppression
Outcome:
Increased levels of both drugs
Mechanism:
Competition for renal tubular secretion
Outcome:
May increase mycophenolic acid levels
Mechanism:
Inhibition of CYP3A4
Most likely new formulation: extended-release formulation for improved patient compliance (Year: 2025, 80% confidence)
Based on current usage trends and clinical trial data, there is a 70% likelihood of expanded indications for mycophenolic acid in autoimmune diseases within the next 5 years.
Immunosuppressant, Antimetabolite
Imidazole carboxamide